GB2597319A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
The cannabidiol (CBD) preparation for use in the treatment of seizures associated with arginase deficiency. The seizures may be focal seizures without impairment and focal seizures with impairment. The preparation may comprise greater than 95% CBD and not more than 0.15% THC. The…
USPTO Abstract
The cannabidiol (CBD) preparation for use in the treatment of seizures associated with arginase deficiency. The seizures may be focal seizures without impairment and focal seizures with impairment. The preparation may comprise greater than 95% CBD and not more than 0.15% THC. The preparation may be used in combination with one or more concomitant anti-epileptic drugs (AEDs), such as levetiracetam, clobazam, rufinamide, topiramate, stiripentol and phenobarbital. The CBD may be isolated from cannabis plant material or as a synthetic preparation. The dose of CBD may be between 5mg/kg/day and 50mg/kg/day. Also claimed is a method of treating seizures associated with MMPSI comprising administering a cannabidiol preparation to the subject in need thereof.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.